Data presented at the 2017 ASH annual meeting revealed that the combination of selinexor and sorafenib appears to be safe with clinical activity in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia.
A recent study showed that molecular tumor boards coupled with cognitive computing with IBM's Watson could improve patient care by providing a rapid, comprehensive approach for data analysis.
Data presented at 2017 ASH showed that mogamulizumab resulted in improved progression free survival (PFS), overall response rates (ORR), and better quality of life in patients with previously treated CTCL compared with vorinostat.
In data presented at 2017 ASH, a highly selective inhibitor of KIT D816V is showing promise for advanced systemic mastocytosis, a hard-to-treat group of poor prognosis mast cell neoplasms.
At the 2017 ASH annual meeting, investigators presented data on the pharmacodynamic effects of copanlisib in patients with NHL and solid tumors that showed dose-dependent on-target activity with the drug.
Researchers presented data at the 2017 ASH annual meeting about their new personalized MDS prediction model that uses clinical and genomic data to help better guide therapy and improve outcomes compared with other models.
A new study has found that inhibiting the METTL3 gene destroys human and mouse acute myeloid leukemia cells without harming non-leukemic blood cells, thereby making it a potential target for new therapies.
Researchers found that high levels of IDO (indoleamine 2, 3 dioxygenase) at diagnosis of AML could also identify those who might benefit most by taking an IDO inhibitor along with their standard therapy.
The OncoArray Consortium, an endeavor involving 550 researchers from 6 continents, identified new target genes that may allow for better definition of the pathways and mechanisms underlying breast cancer susceptibility.
A new study suggests that the protein NFS1 provides a central protection for cancer cells against oxygen and that it may be possible to leverage this discovery into a new lung cancer treatment.